54 results
Page 2 of 3
DEF 14A
xnkv156twh 1iyq8b5uy
30 Apr 21
Definitive proxy
4:02pm
424B5
9mr3tbi v8o
21 Apr 21
Prospectus supplement for primary offering
4:45pm
424B5
lovv64x4
19 Apr 21
Prospectus supplement for primary offering
4:57pm
PRE 14A
hxdnszmqf ir1k2o
14 Apr 21
Preliminary proxy
4:00pm
8-K
EX-99.1
sbe9d2r2
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
EX-99.1
iyyn7e74
1 Mar 21
Zai Lab Announces Financial Results
7:01am
10-K
wtuadpw1xd8iag4ho
1 Mar 21
Annual report
12:00am
10-K
EX-10.20
jafo 6n2s
1 Mar 21
Annual report
12:00am
8-K
EX-99.1
0w19imjv4q04
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
6-K
EX-99.1
dgxr8eik
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
6-K
EX-99.1
2g5ws1t
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
EX-99.1
zklibtxi0206t2wnw0bp
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
EX-99.1
5pmyg6lq9f6
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
p7sh21099f
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
qraq 1fqn
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
EX-99.1
czqpjmp
13 Aug 20
Current report (foreign)
7:30am
6-K
EX-99.1
qt5sbo25736
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
e95ozb m0w9fq5w9m
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am
6-K
EX-99.1
7b1 n94hop5n
13 May 20
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
10:22am